IN THE CLAIMS:

Claim 1 **(currently amended)**: A compound of formula **(I)**:



(I)

wherein:

Ring A is imidazo[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl;

R^2 is attached to a ring carbon and is selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkanoyloxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkanoylamino, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl, *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl, phenyl, heterocyclic group, phenylthio or (heterocyclic group)thio; wherein any C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, phenyl or heterocyclic group may be optionally substituted on carbon by one or more G; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from Q;

m is 0-5; wherein the values of R^2 may be the same or different;

R^1 is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-3}alkyl, C_{2-3}alkenyl, C_{2-3}alkynyl, C_{1-3}alkoxy, C_{1-3}alkanoyl, *N*-(C_{1-3}alkyl)amino, *N,N*-(C_{1-2}alkyl)$_2$amino, C_{1-3}alkanoylamino, *N*-(C_{1-3}alkyl)carbamoyl, *N,N*-(C_{1-2}alkyl)$_2$carbamoyl, C_{1-3}alkylS(O)$_a$ wherein a is 0 to 2, *N*-(C_{1-3}alkyl)sulphamoyl or *N,N*-(C_{1-3}alkyl)$_2$sulphamoyl; wherein any C_{1-2}alkyl, C_{1-3}alkyl, C_{2-3}alkenyl or C_{2-3}alkynyl may be optionally substituted on carbon by one or more J;

n is 0 to 2, wherein the values of R^1 may be the same or different;

Ring B is phenyl or phenyl fused to a C_{5-7}cycloalkyl ring;

$\mathbf{R^3}$ is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{2-6}alkenyl or C_{2-6}alkynyl;

p is 0-4; wherein the values of R^3 may be the same or different;

$\mathbf{R^4}$ is a group A-E-; wherein

A is selected from C_{1-6}alkyl, phenyl, a heterocyclic group, C_{3-8}cycloalkyl, phenylC_{1-6}alkyl, (heterocyclic group)C_{1-6}alkyl or C_{3-8}cycloalkylC_{1-6}cycloalkyl; which C_{1-6}alkyl, phenyl, a heterocyclic group, C_{3-8}cycloalkyl, phenylC_{1-6}alkyl, (heterocyclic group)C_{1-6}alkyl or C_{3-8}cycloalkylC_{1-6}cycloalkyl may be optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R;

E is a direct bond or -O-, -C(O)-, -OC(O)-, -C(O)O-, -N(R^a)C(O)-, -C(O)N(R^a)-, -N(R^a)-, -S(O)$_r$-, -SO_2N(R^a)- or -N(R^a)SO_2-; wherein R^a is hydrogen or C_{1-6}alkyl optionally substituted by one or more D and r is 0-2;

D is independently selected from oxo, halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkanoyloxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkanoylamino, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-6}alkoxycarbonyl, C_{1-6}alkoxycarbonylamino, benzyloxycarbonylamino, *N*-(C_{1-6}alkyl)sulphamoyl and *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl; wherein any C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl or phenyl may be optionally substituted on carbon by one or more K;

q is 0-2; wherein the values of R^4 maybe the same or different; and wherein $p + q \leq 5$;

G, J and K are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl,

N-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl; and

Q and R are independently selected from C_{1-4}alkyl, C_{1-4}alkanoyl, C_{1-4}alkylsulphonyl, C_{1-4}alkoxycarbonyl, carbamoyl, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.

Claim 2 **(currently amended)**: A compound of formula **(I)** according to claim 1 wherein R^1 is bromo or 2-hydroxyethylthio and n is 0-1;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable formed from an available carboxy or hydroxy group ester thereof.

Claim 3 **(currently amended)**: A compound of formula **(I)** according to claim 1 wherein Ring A is imidazo[1,2a]pyrid-3-yl;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.

Claim 4 **(currently amended)**: A compound of formula **(I)** according to claim 1 wherein R^2 is attached to a ring carbon and is selected from fluoro, chloro, bromo, cyano, methyl, methoxy, ethylthio, 2-hydroxyethylthio or 2-dimethylaminoethylthio and m is 0-2; wherein the values of R^2 may be the same or different;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.

Claim 5 **(currently amended)**: A compound of formula **(I)** according to claim 1 wherein R^3 is fluoro, chloro, bromo or sulphamoyl; and p is 1;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.

Claim 6 **(currently amended)**: A compound of formula **(I)** according to claim 1 wherein R^4 is methyl, ethyl, methoxy, methylthio, acetyl, benzyloxy, mesyl, *N,N*-diethylaminoethoxy, 3-*N,N*-dimethylamino-2-hydroxypropoxy, phenoxy, *N*-methylcarbamoyl, *N,N*-dimethylcarbamoyl, *N*-(3-imidazol-1-ylpropyl)carbamoyl, *N*-[3-(2-oxo-pyrrolidin-1-yl)propyl]carbamoyl, 3,5-dioxapiperidin-1-ylsulphonyl, *N*-cyclopropylsulphamoyl, *N*-cyclopropylmethylsulphamoyl, anilinosulphonyl, *N*-pyrimidin-2-ylsulphamoyl, *N*-methylsulphamoyl, *N*-propylsulphamoyl, *N*-(2-methoxyethyl)sulphamoyl, *N*-(2-methylaminoethyl)sulphamoyl, *N*-(2-isopropylaminoethyl)sulphamoyl, *N*-(2-dimethylaminoethyl)sulphamoyl, *N*-(2-diethylaminoethyl)sulphamoyl, *N*-[2-(hydroxyethylamino)ethyl]sulphamoyl, *N*-[2-(diethylaminoethyl)ethyl]sulphamoyl, *N*-(pyrrolidin-1-ylethyl)sulphamoyl, *N*-[2-(1-methylpyrrolidin-2-yl)ethyl]sulphamoyl, *N*-(2-piperidin-1-ylethyl)sulphamoyl, *N*-(2-piperazin-1-ylethyl)sulphamoyl, *N*-(2-morpholinoethyl)sulphamoyl, *N*-(2-imidazol-4-ylethyl)sulphamoyl, *N*-(3-hydroxypropyl)sulphamoyl, *N*-(2,3-dihydroxypropyl)sulphamoyl, *N*-(3-methoxypropyl)sulphamoyl, *N*-(3-aminopropyl)sulphamoyl, *N*-(3-methylaminopropyl)sulphamoyl, *N*-(3-dimethylaminopropyl)sulphamoyl, *N*-(3-diethylaminopropyl)sulphamoyl, *N*-(3-isopropylaminopropyl)sulphamoyl, *N*-(3-*t*-butoxycarbonylaminopropyl)sulphamoyl, *N*-(3-benzyloxycarbonylaminopropyl)sulphamoyl, *N*-[3-(2-oxopyrrolidin-1-yl)propyl]sulphamoyl, *N*-(3-morpholinopropyl)sulphamoyl, *N*-[3-(4-methylpiperazin-1-yl)propyl]sulphamoyl, *N*-(3-imidazol-1-ylpropyl)sulphamoyl or *N*-(5-hydroxypentyl)sulphamoyl; and q is 1;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.

Claim 7 **(currently amended)**: A compound of formula **(I)** according to claim 1 wherein Ring B is phenyl;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.

Claim 8 **(currently amended)**: A compound of formula **(I)** selected from:

2-(4-Sulphamoylanilino)-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;

2-[4-(*N*-Methylsulphamoyl)anilino]-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;

2-{4-[*N*-(2-Methoxyethyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;

2-{4-[*N*-(3-Methoxypropyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;

2-{4-[*N*-(3-Isopropylaminopropyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl) pyrimidine;

2-{4-[*N*-(3-Dimethylaminopropyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl) pyrimidine;

2-{4-[*N*-(2-Dimethylaminoethyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;

2-{4-[*N*-(2-Methylaminoethyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine; or

2-{4-[*N*-(2-Methoxyethyl)sulphamoyl]anilino}-4-[5-(2-hydroxyethylthio)imidazo[1,2a] pyrid-3-yl]pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.

Claim 9 **(currently amended)**: A process for preparing a compound of formula **(I)** according to claim 1, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof, which process (wherein R^1, R^2, R^3, R^4, Ring A, Ring B, m, p, q and n are, unless otherwise specified, as defined in formula **(I)**) comprises of:

a) reaction of a pyrimidine of formula **(II)**:



(II)

wherein L is a displaceable group; with an amine of formula **(III)**:



(III)

b) reacting a pyrimidine of formula **(IV)**:



(IV)

with a compound of the formula **(V)**:



(V)

wherein one of M and Q is a displaceable group X and the other is an metallic reagent Y;

or

c) reacting a compounds of formula **(VI)**:



(VI)

with a compound of formula **(VII)**:



(VII)

wherein R^5 is C_{1-6}alkyl and R^6 is hydrogen or R^1;

and thereafter optionally ~~if necessary~~:

i) converting a compound of the formula **(I)** into another compound of the formula **(I)**;

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group.

Claim 10 **(currently amended)**: A pharmaceutical composition which comprises a compound of formula **(I)** according to any one of claims 1 - 8, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof formed from an available carboxy or hydroxy group, in association with a pharmaceutically-acceptable diluent or carrier.

Claims 11-12 **(cancelled).**

Claim 13 (**currently amended**): A method for treating cancer ~~producing an anti-cancer effect~~ in a warm blooded animal in need thereof which comprises administering to said animal an effective amount of a compound of the formula (I) as claimed in any one of claims 1 – 8, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.

Claims 14-17 **(cancelled).**

Claim 18 **(new)**: A method for inhibiting CDK2 in a warm blooded animal in need thereof which comprises administering to said animal an inhibiting amount of a compound of the formula (I) as claimed in any one of claims 1 – 8, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.